SGLT2 Inhibitors Benefit Older Adults with Chronic Kidney Disease
Audio narration · Coming soon
New research presented at ASN Kidney Week 2026 reveals that sodium-glucose cotransporter 2 (SGLT2) inhibitors provide benefits for adults aged 80 and older with chronic kidney disease. This study highlights that advanced age does not limit the effectiveness of these treatments in managing CKD.
Why this matters
PRISM scored this story 60/100 for interest.
Originally published by gnews